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Editorial
A
Policy Forum published in 
this month’s PLoS Medicine 
highlights an issue that the PLoS
Medicine editors have often debated: 
when research takes place within the 
context of clinical care, how can we 
distinguish which activities constitute 
care, and which research? The World 
Medical Association Code of Medical 
Ethics declares that a physician must 
always “act in the patient’s best interest 
when providing medical care” [1]. Yet 
increasingly physicians also undertake 
research, which involves possibly 
unknown risks and beneﬁts. These 
risks, and the uncertainty of beneﬁt, 
might therefore conﬂict with a patient’s 
best interests. 
In their article, Henderson and 
colleagues [2] identify ﬁve key aspects 
of medical research that should be 
understood by the participants who 
enroll as volunteers. They speciﬁcally 
highlight one particular aspect, 
“therapeutic misconception,” which 
exists when “individuals do not 
understand that the deﬁning purpose 
of clinical research is to produce 
generalizable knowledge.” 
Misinterpretation of the boundary 
between research and care may 
have serious consequences. On the 
part of research participants, such 
misunderstanding might result in 
individuals enrolling in research 
studies believing that their physician 
will offer therapy that is, in the 
doctor’s clinical judgment, the best 
approach for the patient personally, 
rather than a therapy governed by the 
research protocol. In another scenario, 
researchers who offer a treatment that is 
in some way different from standard or 
accepted practice might consider that 
treatment to be “off-label” prescribing, 
or a reﬁnement of a surgical procedure, 
rather than a formal clinical trial, and 
fail to adequately protect the patient 
through ethical review and informed 
consent processes [3]. 
Given the potential for 
misinterpretation of the primary 
purpose of research, which is to collect 
data for the purpose of contributing 
to scientiﬁc knowledge, what are the 
requirements that must be fulﬁlled for 
involvement in a trial to be considered 
ethical? Many ethicists consider that, 
in addition to the crucial safeguards 
outlined in the Declaration of Helsinki 
[4], two additional criteria must be 
fulﬁlled (debated in [5]). Firstly, the 
clinical community as a whole should 
be uncertain as regards which of the 
treatments being compared is better (a 
scenario termed “clinical equipoise”); 
and secondly, completion of the trial 
should be likely to alter the balance of 
that equipoise. Importantly, Henderson 
et al. highlight the researchers’ 
uncertainty with respect to risks and 
beneﬁts as a key dimension of research 
that trial participants must understand 
in order to provide valid consent. 
Typically, editors become involved 
only during the ﬁnal stages of a 
research study, namely its preparation 
for dissemination. Without knowledge 
of speciﬁc prior circumstances, it may 
not be possible for an editor to see from 
the manuscript alone where the line 
should be drawn between research and 
care. However, editors do play a crucial 
role in deciding what information 
needs to be included in a research 
report, so that readers can assess the 
validity of the results and be assured 
that the procedures were ethical. But 
these dilemmas can be complex. 
For example, a patient has been 
treated with a nonstandard course 
of therapy; the results are surprising, 
and the physician wishes to publish 
them. Was this treatment a trial (i.e., 
research), and should ethics committee 
approval and informed consent have 
been sought? Or is this treatment an 
example of “off-label” prescribing 
(i.e., medical care, not research)? One 
possible solution is to specify that when 
a paper is written up and submitted 
to a scientiﬁc journal, by deﬁnition, 
research has been done. Alternatively, 
the editor can try to gain some 
understanding of the clinician’s original 
intent in treating their patient—was 
the treatment thought to be the best 
possible option for that patient at the 
time, or was it given speciﬁcally to 
produce new scientiﬁc knowledge? 
Another example of the unclear 
boundary between research and 
treatment is when researchers submit 
a report describing the impact of a 
health care delivery program (for 
example, a report of delivering 
antiretroviral treatment in prisons 
[6]). Are such program descriptions 
research, requiring prior approval from 
a research ethics committee?
In order to resolve such cases, we 
often seek the advice of the PLoS
Medicine Advisory Group on Publication 
Ethics [7] and the Committee on 
Publication Ethics (http://www.
publicationethics.org.uk/); the 
latter body has an important role in 
providing a forum for journal editors 
from around the world to discuss such 
ethical dilemmas. 
Since the primary purpose of health 
research is to produce knowledge that 
will ultimately improve human health, 
and since participants who enroll in 
studies expect that they will contribute 
to that knowledge, investigators must 
commit to placing their ﬁndings in 
the public domain [4,8]. For clinical 
trials, this commitment now means 
investigators must register basic details 
about every planned trial, as required 
by the International Committee of 
Medical Journal Editors [9] and many 
other journals, including the PLoS 
journals. Acceptable publicly accessible 
How Can We Draw the Line between 
Clinical Care and Medical Research?
The PLoS Medicine Editors
Citation: The PLoS Medicine Editors (2007) How can 
we draw the line between clinical care and medical 
research? PLoS Med 4(11): e340. doi:10.1371/journal.
pmed.0040340
Copyright: © 2007 The PLoS Medicine Editors. This 
is an open-access article distributed under the 
terms of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original 
author and source are credited. 
E-mail: medicine_editors@plos.org
The PLoS Medicine Editors are Virginia Barbour, Paul 
Chinnock, Larry Peiperl, Emma Veitch, and Gavin 
Yamey.PLoS Medicine  |  www.plosmedicine.org 1708 November 2007  |  Volume 4  |  Issue 11  |  e340
registries include ClinicalTrials.gov 
(http://www.clinicaltrials.gov/) and 
the ISRCTN (International Standard 
Randomized Controlled Trial Number) 
Web site (http://www.controlled-trials.
com/isrctn/); these and other public 
registries are now searchable through 
a common portal located on the World 
Health Organization Web site (http://
www.who.int/trialsearch/).
The editors of PLoS Medicine believe 
that open access to research ﬁndings 
is the most direct way of fulﬁlling 
the obligation towards participants 
to produce more widely available 
knowledge. In addition to the reporting 
of clinical trials, however, there is a 
great diversity of other types of clinical 
research that must be reported, and 
at PLoS we are committed to making 
these studies available in our journals. 
At PLoS ONE, the peer-review process 
focuses on the technical quality of the 
work done; PLoS ONE is committed to 
providing a venue for publication of 
the results of all correctly conducted 
and reported trials, irrespective of 
outcome.
In addition, PLoS has just launched 
the PLoS Hub for Clinical Trials 
(http://clinicaltrials.ploshubs.org/); 
this site provides a single point of 
access to the results of trials, and other 
types of research that are relevant to 
trials, from multiple PLoS journals, 
including PLoS ONE. This site, and 
future PLoS Hubs, aims to go beyond 
the traditional conception of a journal 
Web site. Tools are available for 
users to rate, annotate, and discuss 
published articles. Open access ensures 
that research ﬁndings are available 
to patients and the public to read 
and reuse freely. We hope that the 
availability of the ﬁndings of clinical 
studies will help to increase public 
understanding of research, and to 
provide the public with ways in which 
they can comment directly on the work 
that has been done.  
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